Pralsetinib: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

29 April 2025

  • curprev 21:1321:13, 29 April 2025 Alara E. Dagsali talk contribs 24,649 bytes +24,649 Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=pralsetinib |aOrAn=a |drugClass=RET receptor tyrosine kinase inhibitor |indicationType=treatment |indication=of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. |adverseReactions=*Interstitial Lung Disease/Pneumonitis *Hypertension *Hepatotoxicity *Hemorrhagic Events *Tumor Lysis Syndrome *Risk of Im..."
Retrieved from "https://www.wikidoc.org/index.php/Pralsetinib"